Patents by Inventor Erez GREENSTEIN

Erez GREENSTEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS DIRECTED AGAINST RAS-DERIVED RECURRENT NEOANTIGENS AND METHODS OF IDENTIFYING SAME
    Publication number: 20240180966
    Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.
    Type: Application
    Filed: October 27, 2023
    Publication date: June 6, 2024
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yardena SAMUELS, Nir FRIEDMAN, Aviyah PERI, Erez GREENSTEIN, Michal ALON
  • MAGE-A1 SPECIFIC T CELL RECEPTOR AND USES THEREOF
    Publication number: 20230242611
    Abstract: MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR ? chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR ? chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 3, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rachel Lea EISENBACH, David BASSAN, Yosi GOZLAN, Esther TZEHOVAL, Nir FRIEDMAN, Erez GREENSTEIN
  • IDENTIFICATION OF RECURRENT MUTATED NEOPEPTIDES
    Publication number: 20220241331
    Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from the group consisting of 199-210.
    Type: Application
    Filed: May 19, 2020
    Publication date: August 4, 2022
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yardena SAMUELS, Shelly KALAORA, Aviyah PERI, Nir FRIEDMAN, Shlomit REICH-ZELIGER, Erez GREENSTEIN